ZW251, a novel Glypican 3–targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload

Laurence Madera1, Andrea Hernandez Rojas2, Raffaello Colombo2, Alex Wu2, Chayly L. Piscitelli2, Dunja Urosev3, Alysha Bissessur3, Chi Wang Cheng2, Renee Duan2, Catrina Kim3, Kevin Yin4, Vincent Fung5, Kaylee Wu6, Winnie Cheung6, Diego A. Alonso7, Mark E. Peterson7, Daya Siddappa7, Sara Herrnberger7, Stuart D. Barnscher8, Jamie R. Rich9

Author affiliations:
1. Department of Translational Cancer Medicine, Vancouver, BC, Canada. 2. Department of Translational Cancer Medicine, UC, Irvine, CA, USA. 3. Department of Translational Cancer Medicine, MD, Rockville, MD, USA. 4. Department of Translational Cancer Medicine, MA, Boston, MA, USA. 5. Department of Translational Cancer Medicine, Hong Kong, Hong Kong. 6. Department of Translational Cancer Medicine, TX, Houston, TX, USA. 7. Department of Translational Cancer Medicine, PA, Philadelphia, PA, USA. 8. Department of Translational Cancer Medicine, NC, Research Triangle Park, NC, USA. 9. Department of Translational Cancer Medicine, AL, Huntsville, AL, USA.

ZW251: Anti-glypican-3 antibody drug conjugate

ZW251 is an antibody drug conjugate (ADC) consisting of a topoisomerase I inhibitor payload conjugated to an antibody targeting Glypican 3 (GPC3). Topoisomerase I Inhibiting ADCs have demonstrated wide clinical benefit in solid tumors and ZW251 aims to apply this against a target expressed in hepatocellular carcinoma (HCC), a disease with high unmet need and limited treatment options. We demonstrate that ZW251 exhibits desired target-mediated activity in vitro; robust anti-tumor activity against a panel of CDX/PDX HCC models, and favorable pharmacokinetics (PK) in Tg32 human FcRn expressing mice. ZW251 is being assessed in an ongoing non-human primate toxicity study.

Glypican 3 (GPC3) is a compelling ADC target for hepatocellular carcinomas

Glypican 3 (GPC3) is a compelling ADC target for hepatocellular carcinoma (HCC). ZW251 is a novel Glypican 3 (GPC3) targeting ADC consisting of a topoisomerase I inhibitor payload conjugated to an antibody targeting GPC3. Topoisomerase I Inhibiting ADCs have demonstrated wide clinical benefit in solid tumors and ZW251 aims to apply this against a target expressed in hepatocellular carcinoma (HCC), a disease with high unmet need and limited treatment options. The authors demonstrated that ZW251 exhibits desired target-mediated activity in vitro; robust anti-tumor activity against a panel of CDX/PDX HCC models, and favorable pharmacokinetics (PK) in Tg32 human FcRn expressing mice. ZW251 is being assessed in an ongoing non-human primate toxicity study. The study suggests that ZW251 has the potential to treat HCC, but further research is needed to confirm its efficacy and safety in clinical trials.